NewAmsterdam Pharma Company NV (NASDAQ: NAMS) open the trading on Wednesday, with great promise as it jumped 4.58% to $23.98, before settling in for the price of $22.93 at the close. Taking a more long-term approach, NAMS posted a 52-week range of $14.06-$27.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Nevertheless, stock’s Earnings Per Share (EPS) this year is 30.86%. This publicly-traded company’s shares outstanding now amounts to $112.17 million, simultaneously with a float of $62.20 million. The organization now has a market capitalization sitting at $2.69 billion. At the time of writing, stock’s 50-day Moving Average stood at $19.63, while the 200-day Moving Average is $20.64.
NewAmsterdam Pharma Company NV (NAMS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. NewAmsterdam Pharma Company NV’s current insider ownership accounts for 44.60%, in contrast to 57.51% institutional ownership. According to the most recent insider trade that took place on Jul 16 ’25, this organization’s Chief Operating Officer sold 51,043 shares at the rate of 21.10, making the entire transaction reach 1,077,007 in total value, affecting insider ownership by 44,000. Preceding that transaction, on Jul 15 ’25, Company’s Chief Operating Officer sold 47,569 for 21.44, making the whole transaction’s value amount to 1,019,648. This particular insider is now the holder of 44,000 in total.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Revenue Records
NewAmsterdam Pharma Company NV’s EPS increase for this current 12-month fiscal period is 30.86% and is forecasted to reach -1.93 in the upcoming year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Let’s observe the current performance indicators for NewAmsterdam Pharma Company NV (NAMS). It’s Quick Ratio in the last reported quarter now stands at 19.98. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 57.11.
In the same vein, NAMS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.88, a figure that is expected to reach -0.49 in the next quarter, and analysts are predicting that it will be -1.93 at the market close of one year from today.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
[NewAmsterdam Pharma Company NV, NAMS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 86.37% While, its Average True Range was 76.86%.
Raw Stochastic average of NewAmsterdam Pharma Company NV (NAMS) in the period of the previous 100 days is set at 92.19%, which indicates a major rise in contrast to 86.27% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.19 that was lower than 1.25 volatility it exhibited in the past 100-days period.
